JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Griffin, M. J. Articles by Rinder, C. S. Search for Related Content PubMed PubMed Citation Articles by Griffin, M. J. Articles by Rinder, C. S. Related Collections Blood Heart

---

CARDIOVASCULAR ANESTHESIA

The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress

Michael J. Griffin, MRCPI, FFARSI^*, Henry M. Rinder, MD, Brian R. Smith, MD, Jayne B. Tracey, Nancy S. Kriz, Conan K. Li, PhD, and Christine S. Rinder, MD^*

Departments of *Anesthesiology, Laboratory Medicine, Internal Medicine, and Pediatrics, Yale University School of Medicine and Yale-New Haven Hospital, New Haven, Connecticut; and Xylum Corporation, Scarsdale, New York

Address correspondence and reprint requests to Michael J. Griffin, Assistant Professor, Department of Anesthesiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8051. Address e-mail to michael.griffin{at}yale.edu

Platelet dysfunction contributes to blood loss after cardiopulmonary bypass. This study examined the antiplatelet effects of heparin, protamine, and varying heparin/protamine ratios in an in vitrophysiologic model and further elucidated the mechanism of the antiplatelet and anticoagulant effects of protamine. We used the Clot Signature Analyzer (CSA^TM), a system that analyzes coagulation in flowing whole blood, to test two aspects of platelet function, with different concentrations of heparin and protamine, under conditions simulating arterial flow: collagen-induced thrombus formation (CITF) under moderate shear and high shear platelet activation, platelet hemostasis time (PHT). In addition, platelet aggregometry, celite activated clotting time (Hepcon^TM ACT), prothrombin time (PT), and partial thromboplastin time (PTT) were measured. Both PHT and the CITF were prolonged by heparin at 20 µg/mL, protamine at 20 and 40 µg/mL, and heparin/protamine ratios of 1:1 and 1:2, but not at 1:1.5. The Hepcon ACT was prolonged by heparin 20 µg/mL and protamine alone at 20 and 40 µg/mL, was normal at a ratio of 1:1, and was prolonged at 1:1.5 and 1:2. Protamine 80 µg/mL prolonged the PT and PTT. Dependency on thrombin, protein kinase C activation, and nonspecific charge effects were examined. The direct thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone prolonged the PHT and ACT, but not the CITF, whereas the polycationic molecules polyarginine and polylysine prolonged the CITF, but not the PHT. The effect of protamine on the PTT, but not PT, could be shortened by the addition of excess phospholipid. Therefore, heparin inhibits both high shear collagen-independent and moderate shear collagen-dependent platelet activation; however, the latter is not mediated by its antithrombin activity. Protamine’s antithrombin effect may explain its inhibition of platelet activation at high shear stress. Protamine’s nonspecific charge effects are more important for inhibiting moderate shear collagen-induced platelet activation.

Implications: This study suggests that protamine reversal of heparin’s antiplateleteffect occurs within a narrow window because of the direct antiplateleteffects of protamine. Antithrombin effects may explain the inhibition of shearactivation of platelets by both heparin and protamine. Nonspecific chargeeffects of protamine may explain the inhibition of collagen plateletactivation in the presence of medium shear.

This article has been cited by other articles:

				V. G. Nielsen Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann. Thorac. Surg., May 1, 2006; 81(5): 1720 - 1727. [Abstract] [Full Text] [PDF]

				M. Mittermayr, J. Margreiter, C. Velik-Salchner, A. Klingler, W. Streif, D. Fries, and P. Innerhofer Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem(R)): an in vitro study Br. J. Anaesth., September 1, 2005; 95(3): 310 - 316. [Abstract] [Full Text] [PDF]

				J. F.W. Keuren, S. J.H. Wielders, A. Driessen, M. Verhoeven, M. Hendriks, and T. Lindhout Covalently-Bound Heparin Makes Collagen Thromboresistant Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 613 - 617. [Abstract] [Full Text]

				W. C. Oliver Jr Overview of Heparin and Protamine Management and Dosing Regimens in Pediatric Cardiac Surgical Patients Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 387 - 410. [Abstract] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999